Evaluating Safety and Effects of Continuous High-Frequency Oscillatory Ventilation in Awake ICU Patients with Atelectasis

What this Trial Is About

Researchers are evaluating the comfort, safety, and effectiveness of Continuous High-Frequency Oscillation CHFO in awake critically ill patients with atelectasis. CHFO is a device-based therapy that aims to improve lung function by maintaining lung recruitment and optimizing gas exchange at high frequencies with minimal pressure changes. This interventional study focuses on ICU patients who experience common respiratory problems like atelectasis, hypoxemia, and poor sputum clearance. The study involves using the CHFO machine MetaNeb system to provide 10 minutes of high-frequency oscillatory ventilation in awake patients. Before treatment, a belt for electrical impedance tomography EIT is placed to monitor lung function continuously before, during, and after the intervention. Key measurements such as pulse oximetry, heart rate, blood pressure, and arterial blood gas analysis are collected at baseline, throughout treatment, and after the session. Patients also provide subjective ratings of their comfort following the treatment. Participants will be closely monitored with EIT data collected 10 minutes before, during, and 10 minutes after CHFO therapy, alongside vital signs and oxygen levels. The main outcome is the change in lung function assessed by EIT at the end of treatment compared to baseline. Secondary outcomes include oxygen saturation, blood pressure, and patient comfort ratings. The study plans to enroll at least 45 patients with interim analyses after every 5 enrollments to adjust recruitment needs. The total participation includes preparation, treatment, and follow-up assessments within a short timeframe during ICU care.

Physiological Effects and Safety of Continuous High-frequency Oscillatory Ventilation in ICU Patients